the commands study: luspatercept versus epoetin alfa for esa-naïve lower-risk mds-associated anemia
Published 1 year ago • 163 plays • Length 1:47Download video MP4
Download video MP3
Similar videos
-
5:30
commands: luspatercept vs epoetin alfa for anemia in esa-naive lr-mds
-
1:06
commands trial: luspatercept vs epoetin alfa in lower-risk mds
-
3:37
biomarker analysis of luspatercept versus epoetin alfa in lr-mds in the phase iii commands study
-
4:36
commands: luspatercept versus epoetin alfa in lr-mds-associated anemia - results & caveats
-
1:00
findings from the commands study and the approval of luspatercept for lower-risk mds
-
1:06
update on the commands trial: luspatercept is superior to esa-based therapy in lr-mds
-
2:14
trial updates for luspatercept in lr-mds: commands, medalist and elements-mds
-
1:34
follow-up from the commands trial beyond the primary endpoint: luspatercept versus esa-based therapy
-
15:21
morphology of myeloid cells (part 1): neutrophilic sequence
-
13:34
hematology basics: intro to the cbc the erythrocyte portion of the cbc
-
20:12
hematopoiesis | erythropoiesis
-
0:48
an introduction to the maxilus study: the optimal dose of luspatercept in lr-mds
-
2:52
long-term evaluation of luspatercept in esa-intolerant/refractory lr-mds: medalist follow-up study
-
4:21
evaluating luspatercept in combination with esas for the treatment of anemia in lr-mds
-
3:19
an efficacy sub-analysis from the ace-536-mf-001 study of luspatercept for mf-related anemia
-
2:17
insights into the real-world efficacy of luspatercept in patients with lr-mds
-
2:30
medalist: luspatercept and erythropoiesis biomarkers in mds
-
6:04
visualization of blood and the cells it contains